Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Mycobacterium avium subsp. paratuberculosis and multiple sclerosis in Sardinian patients: epidemiology and clinical features.
A cross-sectional survey of patient satisfaction and subjective experiences of treatment with fingolimod.
Antiviral therapy of two patients with chromosomally-integrated human herpesvirus-6A presenting with cognitive dysfunction.
Purine-crosslinked injectable chitosan sponges promote oligodendrocyte progenitor cells' attachment and differentiation.
FDA Drug Safety Communication: FDA warns about cases of rare brain infection with MS drug Gilenya (fingolimod) in two patients with no prior exposure to immunosuppressant drugs
Inducible Expression of a Truncated Form of Tau in Oligodendrocytes Elicits Gait Abnormalities and a Decrease in Myelin: Implications for Selective CNS Degenerative Diseases.
Long-term efficacy of Gilenya® reinforced by new 'no evidence of disease activity' (NEDA-4) analysis in MS patients over seven years
Intrathecal versus Oral Baclofen; a Matched Cohort Study of Spasticity, Pain, Sleep, Fatigue and Quality of Life.
Comparison of antibodies hydrolyzing myelin basic protein from the cerebrospinal fluid and serum of patients with multiple sclerosis.
Mitochondrial immobilization mediated by syntaphilin facilitates survival of demyelinated axons.
Mitochondrial mutations of Leber's hereditary optic neuropathy: a risk factor for multiple sclerosis.
Differential microRNA expression in blood in multiple sclerosis.
Direct effects of secretory products of immune cells on neurons and glia.
Lesional-targeting of neuroprotection to the inflammatory penumbra in experimental multiple sclerosis.
Mesenchymal stem cells engineered to express selectin ligands and IL-10 exert enhanced therapeutic efficacy in murine experimental autoimmune encephalomyelitis.
Strategies for regeneration of components of nervous system: scaffolds, cells and biomolecules.
[Research progresses of monoclonal antibodies therapy in neuromyelitis optica].
Factors associated with clinically significant increased walking time in multiple sclerosis: Results of a survival analysis of short-term follow-up data from a clinical database.
MiR-125a targets effector programs to stabilize Treg-mediated immune homeostasis.
Comment on: Month of birth and risk of multiple sclerosis: confounding and adjustments.
Targeting Dynamic Balance in Falls-Prevention Interventions in Multiple Sclerosis: Recommendations from the International MS Falls Prevention Research Network.
Treatment Adherence and Transitioning Youth in Pediatric Multiple Sclerosis.
The most fulminant course of the Marburg variant of multiple sclerosis-autopsy findings.
The effect of the sphingosine-1-phosphate analogue FTY720 on atrioventricular nodal tissue.
Application of quantitative proteomics technologies to the biomarker discovery pipeline for multiple sclerosis.

Pages